Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: T.Bill who wrote (595)	5/8/1998 3:27:00 PM
From: Paul S.	Read Replies (1) \| Respond to of 1185

I was told that it is standard industry practice not to disclose the financial terms. I am actually quite surprised that Leroche let the company use the value of 86.5 mil in the PR. I cant imagine that IR will give us any further info for fear of upsetting Leroche. I looked at FMI(Forbes Meditech) news. They too did not disclose any dollar values. This is an excerpt from their release __________________________________________________________________ Jan. 29 - FMI.VSE - NOVARTIS NUTRITION SIGNS AGREEMENT WITH FORBES MEDI-TECH FOR NOVEL FUNCTIONAL FOOD INGREDIENT Vancouver, BC - Forbes Medi-Tech (VSE: FMI) today announced that it has signed an Agreement with Novartis, a world leader in life sciences, regarding Forbes' unique plant-based sterol composition(FCP), a potential functional food ingredient for lowering cholesterol. Under the agreement, Novartis has paid Forbes a lump sum fee for the exclusive option to a worldwide license to use or sub-license FCP for use in nutritional products. Further financial terms were not disclosed. Thomas Ebeling, Head of Novartis Nutrition worldwide, commented: "This agreement is just a first step in pursuing our science-based nutrition strategy. Once developed with scientifically proven benefits and supported by appropriate marketing, FCP could be a major breakthrough in the high-potential area of functional foods". ____________________________________________________________________ This is the same sort of deal as NRT. Both are agreements with the option to license. (It is industry standard option with upfront and milestone payments) Only a matter of time before NRT rebounds from todays pressure selling. I for one am a buyer at these levels because with a partner like Leroche backing them up, NRT is on their way. Next stop TSE, where we get to play with the big boys!

To: T.Bill who wrote (595)	5/8/1998 5:44:00 PM
From: Mr. Forthright	Respond to of 1185

This is totally normal and reasonable. Yes it will be in the financials at the end of the next quarter. It is OK for insiders to have info that is not available to the public and not release it in certain circumstances such as when negotiations are going on or confidentiality agreements are signed. As long as they don't trade on that info and don't tip-off investors it is OK. What is not normal is the fact that somebody here knew the Hoffman deal was coming and he/she tipped-off investors. THAT IS REAL BAD.